FOR IMMEDIATE RELEASE — April 24, 2026
Capital to accelerate platform expansion and customer success.
About the announcement
Maxis AI continues to expand its footprint across regulated clinical operations, partnering with sponsors, CROs, and site networks to bring governed agentic AI into production environments. Today's news reflects continued momentum across the company's platform, services, and customer outcomes.
The company's agentic platform is deployed across clinical data management, biometrics, oversight, and submission readiness, with full audit trails and reviewer-in-the-loop governance designed for GxP environments.
Customer impact
Across deployments to date, customers have reported 30–45% reductions in database lock cycle time, multi-million-dollar cost recovery per pivotal trial, and earlier portfolio-level risk detection. These outcomes are validated against pre-deployment baselines and tracked through customer-specific quarterly business reviews.
- Top-20 pharma sponsors using Maxis AI agents in production CDM and biometrics workflows.
- Multiple global CROs adopting governed agentic delivery inside FSP biometrics engagements.
- Rare-disease site networks meeting enrollment milestones ahead of plan.
Leadership commentary
"Our customers are not looking for another tool. They are looking for governed execution that holds up to internal audit and regulatory inspection. That is what Maxis AI delivers, and it is why we are seeing this level of adoption."
About Maxis AI
Maxis AI builds governed agentic AI for clinical trials. The company partners with the world's leading pharma sponsors, CROs, and site networks to recover cycle time, cost, and quality across the trial lifecycle. Learn more at maxis.ai.
About the author
Maxis AI Newsroom
Press & Communications
Official announcements, press releases, and media coverage from the Maxis AI communications team.
